According to related industries, Lilly and Ildong Pharmaceutical's Reyvow passed the Drug Commission (DC) of medical institutions such as Kangwon National University Hospital, Nowon-eulji Hospital, and Sinchon Severance Hospital, and advanced general hospitals such as Seoul National University Hospital, Asan Medical Center, and Seoul St. Mary's Hospital are also undergoing procedures. Reyvow is attracting attention as an expected replacement for tryptan-based drugs, which are most commonly used to treat migraines.

This drug targets serotonin (5-HT) 1F receptors like conventional tryptan drugs, but has the advantage of not having cardiovascular side effects by acting selectively. On the other hand, tryp